Two Corticosteroid-Free Regimens—Tacrolimus Monotherapy after Basiliximab Administration and Tacrolimus/Mycophenolate Mofetil—in Comparison with a Standard Triple Regimen in Renal Transplantation: Results of the Atlas Study
The DOI matches its Crossref record.
Abstract
BACKGROUND: The side effects associated with corticosteroids have led to efforts to minimize their use in renal transplant patients. In this study we compared two corticosteroid-free tacrolimus-based regimens with a standard triple therapy. METHODS: This was a 6-month, phase III, open-label, parallel-group, multicenter study. The total analysis set comprised 451 patients, randomized (1:1:1) to receive tacrolimus (Tac) monotherapy following basiliximab (Bas) administration (n=153), Tac/mycophenolate mofetil (MMF) (n=151), or, Tac/MMF/corticosteroids triple therapy as a control (n=147). RESULTS: The study was completed by 91.2% (triple therapy), 94.7% (Tac/MMF), and 82.4% (Bas/Tac) of patients. Patient baseline characteristics were similar in all groups. The incidences of biopsy-proven acute rejection were 8.2% (triple therapy), 30.5% (Tac/MMF), and 26.1% (Bas/Tac), p<0.001 (multiple test for comparison with triple therapy); Bas/Tac vs. Tac/MMF, p=ns. The incidences of corticosteroid-resistant acute rejection were 2.0%, 4.0%, and 5.2%, p=ns. Graft survival (95.9%, 96.7%, and 94.7%, p=ns) and patient survival (100%, 99.3%, and 99.3%, p=ns) were similar in all groups. Median serum creatinine at month 6 was 123.0 micromol/L (triple therapy), 134.7 micromol/L (Tac/MMF) and 135.8 micromol/L (Bas/Tac). The overall safety profiles were similar; differences (p<0.05) were reported for anaemia (24.5% vs. 12.6% vs. 14.5%), diarrhoea (12.9% vs. 17.9% vs. 5.9%), and leukopenia (7.5% vs. 18.5% vs. 5.9%) for the triple therapy, Tac/MMF, and Bas/Tac group, respectively. The incidences of new-onset diabetes mellitus were 4.6%, 7.1%, and 1.4%, respectively. CONCLUSION: Corticosteroid-free immunosuppression was feasible with the Bas/Tac and the Tac/MMF regimens. Both corticosteroid-free regimens were equally effective in preventing acute rejection, with the Bas/Tac therapy offering some safety benefits.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cited by
Interleukin 2 receptor antagonists for kidney transplant recipients
Webster, A. C., Ruster, L. P., McGee, R. G., Matheson, S. L., Higgins, G. Y., Willis, N. S., Chapman, J. R., & Craig, J. C. (2010) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd003897.pub3 · Cited by 268
Knight, S. R., & Morris, P. J. (2010) · Transplantation · doi:10.1097/tp.0b013e3181c518cc · Cited by 265
Steroid avoidance or withdrawal for kidney transplant recipients
Haller, M. C., Royuela, A., Nagler, E. V., Pascual, J., & Webster, A. C. (2016) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd005632.pub3 · Cited by 258
Nelson, J., Alvey, N., Bowman, L., Schulte, J., Segovia, M. C., McDermott, J., Te, H. S., Kapila, N., Levine, D. J., Gottlieb, R. L., et al. (2022) · Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy · doi:10.1002/phar.2716 · Cited by 130
Metadata
- Authors
- Vítko, S., Klinger, M., Salmela, K., Wlodarczyk, Z., Tydèn, G., Senatorski, G., Ostrowski, M., Fauchald, P., Kokot, F., Stefoni, S., Perner, F., Claesson, K., Castagneto, M., Heemann, U., Carmellini, M., Squifflet, J.-P., Weber, M., Segoloni, G., Bäckman, L., Sperschneider, H., & Krämer, B. K.
- Venue
- Transplantation
- Published
- 2005-12-27
- Volume
- 80
- Issue
- 12
- Pages
- 1734-1741
- ISSN
- 0041-1337 (ISSN-L)
- OpenAlex
- W1992241917
- Cited by
- 113
- References
- 0
- FWCI
- 3.55
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Two Corticosteroid-Free Regimens—Tacrolimus Monotherapy after Basiliximab Administration and Tacrolimus/Mycophenolate Mofetil—in Comparison with a Standard Triple Regimen in Renal Transplantation: Results of the Atlas Study. https://app.cochat.ai/papers/10.1097/01.tp.0000188300.26762.74
- The paper
- Vítko, S., Klinger, M., Salmela, K., Wlodarczyk, Z., Tydèn, G., Senatorski, G., Ostrowski, M., Fauchald, P., Kokot, F., Stefoni, S., Perner, F., Claesson, K., Castagneto, M., Heemann, U., Carmellini, M., Squifflet, J.-P., Weber, M., Segoloni, G., Bäckman, L., . . . Krämer, B. K. (2005). Two Corticosteroid-Free Regimens—Tacrolimus Monotherapy after Basiliximab Administration and Tacrolimus/Mycophenolate Mofetil—in Comparison with a Standard Triple Regimen in Renal Transplantation: Results of the Atlas Study. Transplantation. https://doi.org/10.1097/01.tp.0000188300.26762.74
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.